Pre-clinical studies showed that immune and MM cells from patients present higher expression of PD-1 and PD-L1 than healthy individuals, and that the blockade of PD-1/PD-L1 abrogates MM growth, which is further enhanced with lenalidomide combination [103]. Here, CD274 is linked to Miyoshi myopathy.